Hamostaseologie
DOI: 10.1055/a-2238-4744
Mirjana Kovac
1
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
2
Department of Hemostasis, Blood Transfusion Institute of Serbia, Belgrade, Serbia
,
Milena Todorovic Balint
1
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
3
Clinic for hematology, University Clinical Centre of Serbia, Belgrade, Serbia
,
Marija Milenkovic
1
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
4
Emergency Centre, University Clinical Centre of Serbia, Belgrade, Serbia
,
Dusica Basaric
2
Department of Hemostasis, Blood Transfusion Institute of Serbia, Belgrade, Serbia
,
Branko Tomic
5
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia
,
Bela Balint
1
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
6
Faculty of Medicine of the Military Medical Academy, University of Defense, Belgrade, Serbia
,
Vera Ignjatovic
7
Johns Hopkins All Children's Institute for Clinical and Translational Research, United States
8
Johns Hopkins University School of Medicine, St. Petersburg, Florida, United States
› Author Affiliations
Funding This study was supported by grant 451-03-47/2023-01/200042 from the Ministry of Science, Technological Development and Innovations, Serbia.
› Further Information
Also available at
![SFX Search]()
Permissions and Reprints
Abstract
Changes in the hemostatic system during COVID infection lead to hypercoagulability. Numerous studies have evaluated hemostatic abnormalities in COVID patients during acute infection, in the period of hospitalization. However, the hemostatic status following hospital discharge has not been sufficiently assessed. Considering the importance of FVIII and D-dimer levels as markers for the assessment of thrombosis, our study aimed to evaluate changes in these markers, as well as the influence of patient's age and clinical presentation of COVID infection on those hemostatic markers in the post-COVID phase. This prospective study (July 2020 to December 2022) included 115 COVID patients, 68 (59%) with asymptomatic/mild and 47 (41%) with moderate/severe clinical presentation. Patient follow-up included laboratory evaluation of FVIII and D-dimer levels at 1, 3, and 6 months following the COVID infection. Three months after the COVID infection, elevated FVIII was recorded in 44% of younger versus 65% of older individuals, p = 0.05, respectively, and 30 versus 57% (p = 0.008) 6 months post–COVID infection. With a focus on clinical presentation, a higher number of patients with moderate/severe COVID had elevated FVIII activity, but a statistically significant difference was observed only for the 6 months (32% mild vs. 53% moderate/severe, p = 0.041) post-infection time point. Following a COVID infection, an increase in FVIII activity suggests a continued hypercoagulable state in the post-COVID period and correlates with elevated D-dimer levels. This increase in FVIII is more pronounced in patients with moderate/severe clinical picture and those patients older than 50 years.
Keywords
hypercoagulability -
venous thrombosis -
infectious diseases -
factor VIII
Publication History
Received: 12 June 2023
Accepted: 03 January 2024
Article published online:
01 March 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Stuttgart · New York
References
1
Bahraini M,
Dorgalaleh A.
The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
2
Schulman S.
Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost 2020; 46 (07) 772-776
3
Langer F,
Kluge S,
Klamroth R,
Oldenburg J.
Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hamostaseologie 2020; 40: 264-269
4
Han H,
Yang L,
Liu R.
et al.
Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58 (07) 1116-1120
5
Panigada M,
Bottino N,
Tagliabue P.
et al.
Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18 (07) 1738-1742
6
von Meijenfeldt FA,
Havervall S,
Adelmeijer J.
et al.
Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Res Pract Thromb Haemost 2020; 5 (01) 132-141
7
Stefely JA,
Christensen BB,
Gogakos T.
et al.
Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism. Am J Hematol 2020; 95 (12) 1522-1530
8
von Meijenfeldt FA,
Havervall S,
Adelmeijer J.
et al.
Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv 2021; 5 (03) 756-759
9
Fei Y,
Tang N,
Liu H,
Cao W.
Coagulation dysfunction. Arch Pathol Lab Med 2020; 144 (10) 1223-1229
10
Zhou F,
Yu T,
Du R.
et al.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
11
Milenkovic M,
Hadzibegovic A,
Kovac M.
et al.
D-dimer, CRP, PCT, and IL-6 levels at admission to ICU can predict in-hospital mortality in patients with COVID-19 pneumonia. Oxid Med Cell Longev 2022; 2022: 8997709
12
Klok FA,
Kruip MJHA,
van der Meer NJM.
et al.
Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
13
Middeldorp S,
Coppens M,
van Haaps TF.
et al.
Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1995-2002
14
Di Minno A,
Ambrosino P,
Calcaterra I,
Di Minno MND.
COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020; 46 (07) 763-771
15
Kovac M,
Mitic G,
Milenkovic M.
et al.
Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection. Thromb Res 2022; 218: 151-156
16 WHO Working Group on the Clinical Characterization and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20: e192-e197
17
Koster T,
Blann AD,
Briët E,
Vandenbroucke JP,
Rosendaal FR.
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345 (8943) 152-155
18
Di Gennaro L,
Valentini P,
Sorrentino S.
et al.
Extended coagulation profile of children with long COVID: a prospective study. Sci Rep 2022; 12 (01) 18392
19
Turner NA,
Moake JL.
Factor VIII is synthesized in human endothelial cells, packaged in Weibel-Palade bodies and secreted bound to ULVWF strings. PLoS One 2015; 10 (10) e0140740
20
Zuin M,
Barco S,
Giannakoulas G.
et al.
Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis. J Thromb Thrombolysis 2023; 55 (03) 490-498
Comments (0)